Semaglutide: What to Know Before Compounding

In the National Association of Boards of Pharmacy’s (NABP) Innovations publication, government and regulatory partner Libby Baney and counsel Jonathan Keller, PharmD, coauthored an article on what boards of pharmacy and other stakeholders should know about compounded semaglutide products.

In the article, Baney and Keller provide an overview of semaglutide, the scenarios in which it can be compounded, and the criteria for compounding. The authors also outline issues to consider before compounding semaglutide, actions taken by boards of pharmacy, and what comes next.